June 2017 dataset released at EGA

The Centre for Epigenome Mapping Technologies project page at EGA has been updated with the following new data from our Vancouver mapping centre:

ChIP-Seq data for the following samples:

  • CEMT_86: normal thyroid (matched to CEMT_87)
  • CEMT_87: thyroid papillary carcinoma (matched to CEMT_86)
  • CEMT_88: normal thyroid (matched to CEMT_89)
  • CEMT_89: thyroid papillary carcinoma (matched to CEMT_88)
  • CEMT_90: normal thyroid (matched to CEMT_91)
  • CEMT_91: thyroid papillary carcinoma (matched to CEMT_90)
  • CEMT_94: CD19+ CLL cells
  • CEMT_96: CD19+ CLL cells
  • CEMT_97: CD19+ CLL cells
  • CEMT_98: normal thyroid (matched to CEMT_99)
  • CEMT_99: thyroid goiter (matched to CEMT_98)
  • CEMT_129: normal tonsil B cells

miRNA-Seq data for the following samples:

  • CEMT_62: malignant colon adenoma
  • CEMT_68: colon, diverticulitis
  • CEMT_72: normal colon
  • CEMT_73: malignant glioma
  • CEMT_74: malignant glioma
  • CEMT_75: malignant glioma
  • CEMT_76: malignant glioma
  • CEMT_78: malignant glioma
  • CEMT_79: malignant glioma
  • CEMT_80: malignant glioma
  • CEMT_81: malignant glioma
  • CEMT_86: normal thyroid (matched to CEMT_87)
  • CEMT_87: thyroid papillary carcinoma (matched to CEMT_86)
  • CEMT_88: normal thyroid (matched to CEMT_89)
  • CEMT_89: thyroid papillary carcinoma (matched to CEMT_88)
  • CEMT_90: normal thyroid (matched to CEMT_91)
  • CEMT_91: thyroid papillary carcinoma (matched to CEMT_90)
  • CEMT_94: CD19+ CLL cells
  • CEMT_95: CD19+ CLL cells
  • CEMT_96: CD19+ CLL cells
  • CEMT_97: CD19+ CLL cells
  • CEMT_98: normal thyroid (matched to CEMT_99)
  • CEMT_99: thyroid goiter (matched to CEMT_98)
  • CEMT_129: normal tonsil B cells
  • CEMT_130: normal thyroid (matched to CEMT_131)
  • CEMT_131: thyroid goiter (matched to CEMT_130)
  • CEMT_132: normal thyroid (matched to CEMT_133)
  • CEMT_133: thyroid goiter (matched to CEMT_132)

Data access application instructions and terms of use are available from the EGA site. Please contact us with any questions.